Clinical trials: Light Chain (AL) Amyloidosis
Relapsed or Refractory Multiple Myeloma
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
- Trial name
- NCT05503550
- Testing
- Talquetamab
- Sponsor
- Janssen Research & Development, LLC
Cardiac Amyloidosis
International Cardiac Amyloidosis Registry
Cardiac amyloidosis is a relatively rare disease. However, with the newer imaging techniques that have become available to us in recent years, determining the diagnosis is becoming more common. There are several variants.
- Trial name
- ICAR (NCT06894290)
- Where
- 6 sites in Belgium, Italy and 3 more
- Volunteers
- 300 people
- Sponsor
- Leiden University Medical Center
AL Amyloidosis, Smoldering Multiple Myeloma
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to: 1.
- Conditions
- AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- ProDigALIty (NCT06383143)
- Testing
- no intervention
- Where
- 4 sites in Italy
- Volunteers
- 760 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Light Chain (AL) Amyloidosis
Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)
Venetoclax is considered as a promising agent for light-chain (AL) amyloidosis due to the high percentage of t(11;14). Several retrospective studies showed venetoclax-based therapy could induce rapid and profound hematologic…
- Trial name
- NCT06629818
- Testing
- Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous), Venetoclax, Dexamethasone
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Peking Union Medical College Hospital
Recurrent AL Amyloidosis, Refractory AL Amyloidosis
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
This phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and dexamethasone in treating patients with light chain amyloidosis that has come back (relapsed) or does not…
- Trial name
- NCT04847453
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography
- Where
- 16 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Primary Systemic Amyloidosis
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis.
- Trial name
- DUAL (NCT02207556)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical College of Wisconsin
Amyloidosis
A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
This study is designed to assess the repeatability of organ-specific quantitation of radiotracer uptake following Positron Emission Tomography/Computed Tomography (PET/CT) imaging of AT- 01 in subjects with amyloid light chain…
- Trial name
- AT01-001 (NCT05235269)
- Testing
- 124I-AT-01
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Attralus, Inc.
AL Amyloidosis, Light Chain (AL) Amyloidosis
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
This phase I/II trial tests the safety, side effects, and best dose of venetoclax, daratumumab, and dexamethasone for the treatment of systemic light-chain amyloidosis in patients with a deoxyribonucleic acid (DNA) abnormality…
- Conditions
- AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
- Trial name
- NCT05486481
- Testing
- Venetoclax, Dexamethasone, Daratumumab
- Sponsor
- Alfred Chung, MD
Multiple Myeloma, Smoldering Multiple Myeloma
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or…
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
- Trial name
- NCT06768489
- Testing
- JNJ-79635322, Daratumumab, Pomalidomide
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 276 people
- Sponsor
- Janssen Research & Development, LLC
AL Amyloidosis
A Registry of AL Amyloidosis (ReAL)
The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.
- Trial name
- ReAL (NCT04839003)
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
AL Amyloidosis
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
This is an open-label, multicenter, Phase 2 study in subjects with previously treated patients with light chain (AL) amyloidosis in need for therapy. Approximately 35 subjects will receive therapy with belantamab mafodotin.
- Trial name
- EMN27 (NCT04617925)
- Testing
- Belantamab mafodotin
- Where
- 6 sites in France, Germany and 4 more
- Volunteers
- 35 people
- Sponsor
- Stichting European Myeloma Network
Systemic Amyloidosis
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamyloid deposits in patients with AL or ATTR-associated systemic…
- Trial name
- NCT05951816
- Testing
- 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Tennessee Graduate School of Medicine
Primary Amyloidosis
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and pharmacokinetics of NEOD001 in 25 additional subjects at…
- Trial name
- NCT01707264
- Testing
- NEOD001
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- Prothena Biosciences Ltd.
AL Amyloidosis
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
This phase 2 study ain to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy.
- Trial name
- IsAMYP (NCT05066607)
- Testing
- Isatuximab
- Where
- 15 sites in France
- Volunteers
- 46 people
- Sponsor
- Intergroupe Francophone du Myelome
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04504825
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 125 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Amyloidosis, Light Chain (AL) Amyloidosis
Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis
Patients with systemic light chain (AL) amyloidosis, particularly those who are ineligible for transplant or have relapsed/refractory disease, have limited treatment options.
- Trial name
- NCT04943302
- Testing
- Bendamustine Hydrochloride, Isatuximab
- Sponsor
- Tufts Medical Center
Recurrent Primary Amyloidosis
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
This randomized phase II trial studies how well lenalidomide, dexamethasone, and eotuzumab with or without cyclophosphamide work in treating patients with primary amyloidosis that has come back after a period of improvement.
- Trial name
- NCT03252600
- Testing
- Cyclophosphamide, Dexamethasone, Elotuzumab
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Amyloidosis
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .
- Trial name
- ALANIS (NCT07224672)
- Testing
- Belantamab mafodotin, Cyclophosphamide, Bortezomib
- Where
- 5 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline